Table 2 Standardised Incidence Ratios (SIRs) and Absolute Excess Risks (AERs) of subsequent primary neoplasms among patients with bone sarcoma in Sweden by calendar year at diagnosis, age at diagnosis, site and follow-up.
All | Osteosarcoma | Ewing sarcoma | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Person years | No. Obs/exp | SIR (95% CI) | AER (95% CI) | No. Obs/exp | SIR (95% CI) | AER (95% CI) | No. Obs/exp | SIR (95% CI) | AER (95% CI) | |
Overall | 16,170 | 104/47 | 2.2 (1.8–2.7) | 35.1 (23.3–48.7) | 75/40.4 | 1.9 (1.5–2.3) | 30.7 (16.5–47.5) | 29/6.8 | 4.2 (2.8–6.1) | 45.4 (25.8–71.3) |
Sex | ||||||||||
Male | 9332 | 48/25.6 | 1.9 (1.4–2.5) | 24.0 (10.5–40.1) | 38/22.4 | 1.7 (1.2–2.3) | 24.5 (7.1–46.7) | 10/3.3 | 3.1 (1.5–5.7) | 22.8 (5.2–51.2) |
Female | 6839 | 56/21.6 | 2.6 (2.0–3.4) | 50.3 (30.2–74.7) | 37/18.0 | 2.1 (1.4–2.8) | 38.6 (16.3–67.1) | 19/3.6 | 5.3 (3.2–8.3) | 80.0 (40.7–135) |
Calendar year at diagnosis | ||||||||||
1958–1979 | 7003 | 50/25.3 | 2.0 (1.5–2.6) | 35.3 (16.9–58.0) | 36/22.4 | 1.6 (1.1–2.2) | 25.1 (5.2–50.5) | 14/2.9 | 4.8 (2.6–8.1) | 70.9 (30.4–132) |
1980–1999 | 6554 | 41/15.6 | 2.6 (1.9–3.6) | 38.8 (21.1–61.1) | 29/12.7 | 2.2 (1.5–3.3) | 38.4 (15.8–68.2) | 12/2.9 | 4.1 (2.1–7.2) | 39.5 (14.3–78.3) |
2000–2015 | 2613 | 13/6.4 | 2.0 (1.1–3.5) | 25.4 (2.1–60.7) | 10/5.3 | 1.9 (0.9–3.5) | 29.2 (−3.3 to 81.6) | 3/1.1 | 2.9 (0.6–8.3) | 19.3 (-4.3 to 76.3) |
Age at diagnosis | ||||||||||
0–9 years | 2125 | 8/1.2 | 6.5 (2.8–12.8) | 31.9 (10.5–68.4) | 4/0.6 | 6.7 (1.8–17.2) | 34.2 (5.0–96.9) | 4/0.6 | 6.3 (1.7–16.2) | 29.8 (4.0–85.0) |
10–19 years | 8020 | 37/10.4 | 3.6 (2.5–4.9) | 33.2 (19.5–50.6) | 20/8.0 | 2.5 (1.5–3.8) | 21.0 (7.3–40.2) | 17/2.4 | 7.2 (4.2–11.6) | 62.8 (32.4–107) |
≥20 years | 6025 | 59/35.6 | 1.7 (1.3–2.1) | 38.8 (15.5–67.2) | 51/31.7 | 1.6 (1.2–2.1) | 41.8 (13.5–76.7) | 8/3.9 | 2.1 (0.9–4.1) | 29.2 (−2.8 to 83.8) |
Site | ||||||||||
Extremity | 12,683 | 80/38.6 | 2.1 (1.6–2.6) | 32.7 (19.6–48.1) | 63/34.5 | 1.8 (1.4–2.3) | 28.5 (13.9–46.1) | 17/4.1 | 4.2 (2.4–6.7) | 48.1 (21.7–86.1) |
Central | 2949 | 19/6.7 | 2.9 (1.7–4.5) | 41.9 (16.2–78.1) | 9/4.4 | 2.0 (0.9–3.9) | 48.3 (−3.2 to 134) | 10/2.2 | 4.5 (2.2–8.3) | 38.8 (12.8–80.7) |
Pelvic | 1119 | 7/1.9 | 3.8 (1.5–7.8) | 45.9 (8.5–112) | 3/1.3 | 2.3 (0.5–6.6) | 49.5 (−21.1 to 221) | 4/0.5 | 7.6 (2.1–19.4) | 44.4 (7.2–124) |
Non-pelvic central | 1830 | 12/4.8 | 2.5 (1.3–4.4) | 39.4 (7.7–88.4) | 6/3.1 | 1.9 (0.7–4.2) | 47.7 (−14.6 to 163) | 6/1.7 | 3.5 (1.3–7.7) | 35.2 (4.1–93.1) |
Follow-up, years | ||||||||||
0–5 | 5085 | 25/10.5 | 2.4 (1.5–3.5) | 28.5 (11.2–51.9) | 16/9.4 | 1.7 (1.0–2.8) | 19.7 (−0.8 to 49.6) | 9/1.1 | 8.4 (3.8–15.9) | 45.4 (17.4–91.7) |
5–30 | 9292 | 58/22.3 | 2.6 (2.0–3.4) | 38.4 (23.4–56.7) | 42/18.7 | 2.2 (1.6–3.0) | 35.8 (17.8–58.4) | 16/3.6 | 4.4 (2.5–7.2) | 44.7 (20.0–80.7) |
>30 | 1793 | 21/14.5 | 1.5 (0.9–2.2) | 36.5 (−8.1 to 98.4) | 17/12.3 | 1.4 (0.8–2.2) | 32.9 (−16.8 to 105) | 4/2.2 | 1.9 (0.5–4.8) | 50.4 (−28.9 to 221) |
